HRAS and head and neck squamous cell carcinoma: As tipifarnib demonstrates good clinical efficacies in HRAS-mutated HNSCC, salivary gland carcinoma, and urothelial carcinoma48,52,53, other RAS genes have gained attention for precision medicine development.